Found 11 Pathology trials
A listing of Pathology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
CART-38 in Adult AML and MM Patients
See protocol section 2 See protocol section 2 See protocol section 2
Veri-T-001
This is a phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy study of oral verdiperstat (BHV-3241) in patients with semantic variant Primary Progressive Aphasia (svPPA) due to Frontotemporal Lobar Degeneration with TDP-43 pathology (FTLD-TDP).
Circulating Biomarkers for Glioma
Subjects will be recruited from the Radiation Oncology and Neurosurgery practices at the Hospital of the University of Pennsylvania. The treating radiation oncologist will determine if the patient is a potential research candidate and has the capacity to consent. The goal of this study is to collect and analyze blood …
FES in Uterine Cancer
Primary Objectives Evaluate utility of FES PET/CT to detect estrogen receptor (ER+) uterine cancer lesions in patients with recurrent or metastatic uterine cancer Secondary Objectives Evaluate utility of FES PET/CT compared to standard axial cross-sectional imaging and/or FDG PET/CT when available to establish tumor heterogeneity and staging Correlate FES uptake …
Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial
COSMID is a pragmatic, patient-level randomized superiority trial of elective colectomy vs. best medical management for patients with quality of life (QoL) limiting diverticular disease. The goal of the COSMID trial is to answer the question: For patients with QoL-limiting diverticular disease, is elective colectomy more effective than best medical …
Immunologic Analysis of Thoracic Duct Lymph from MS Patients and Controls
This study aims to investigate the benefits of collecting lymph in addition to blood in patients with multiple sclerosis (MS). It is now well recognized that the central nervous system (CNS) is not as immune privileged as it has been considered. A system of lymphatic drainage has been described both …
FES PET/CT in Endocrine Refractory Breast Cancer
Patients with recurrent or metastatic ER+ breast cancer, who have failed prior endocrine therapy may be eligible for this study. Patients may participate in this study, if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. …
PennRad BioBank
800x600 Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 Normal 0 false false false EN-US X-NONE X-NONE The goal of this study is to collect tissue and/or blood that may be used to identify gene, protein and enzyme markers that will predict cells’ response to breast cancer treatment. Tissue …
UPCC 02619: Adjuvant Nivolumab Or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Phase 2
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
1 - 10 of 11
- 1
- 2
